In the context of FRDA, preclinical in vitro and in vivo experiments provided proof of concept that these molecules can induce frataxin expression in different models of FRDA (Herman et al., 2006; Chan et al., 2013; Soragni et al., 2014). The gene discussed is FXN; the disease is Friedreich ataxia.